FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Ins	conditions of Rule truction 10.						
1. Name and Addres <u>Korenberg Ma</u>	s of Reporting Person*		2. Issuer Name <b>and</b> Ticker or Trading Symbol PALVELLA THERAPEUTICS, INC. [ PVLA ]		tionship of Reporting Pers all applicable) Director	on(s) to Issuer	
(Last) (First) (Middle) C/O PALVELLA THERAPEUTICS, INC.		` ,	3. Date of Earliest Transaction (Month/Day/Year) 12/13/2024	X	Officer (give title below)  CFO, Trea	Other (specify below)	
125 STRAFFORD DRIVE, SUITE 360		60	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line  X Form filed by One Reporting Person			
(Street)					Form filed by More than	n One Reporting Person	
WAYNE	PA	19087			, , , , , , , , , , , , , , , , , , , ,		
(City)	(State)	(Zip)					

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(	2. Transaction Date (Month/Day/Year)	, ,	Execution Date, Transaction					Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$13.6	12/13/2024		A		167,100		(1)	12/13/2034	Common Stock	167,100	\$0	167,100	D	

#### Explanation of Responses:

 $1.\,25\% \ of \ the \ stock \ options \ will \ vest \ on \ October \ 16, 2025, \ and \ the \ remaining \ 75\% \ will \ vest \ in \ equal \ monthly \ tranches \ over \ the \ following \ 36 \ months.$ 

/s/ Kathleen A. McGowan, Attorney-in-Fact 12/17/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).